Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2172 | Region: Global | Published Date: July, 2001
Pages: 157 |Tables: 65 |Figures: 75

Dry Eye Disease Market Insights

Dry Eye Disease Market size was valued at USD 5.13 billion in 2019 and is poised to grow from USD 5.53 billion in 2023 to USD 10.92 billion by 2031, growing at a CAGR of 7.85% in the forecast period (2024-2031).

Dry eye is an ocular surface disease that causes the eye to produce insufficient tears and is associated with symptoms of ocular discomfort. Keratitis sicca, keratoconjunctivitis sicca (KCS), xerophthalmia, dry eye syndrome (DES), and dysfunctional tear syndrome are all names for dry eye disease (DTS). Clinical trials and research and development activities are expected to gain traction in order to increase the penetration of dry eye treatments and medications.

Dry eye disease affects a significant proportion of the global population (from middle to old age). Women are more likely than men to contract the disease. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double between 2015 and 2050, rising from 12% to 22%. By 2050, low- and middle-income countries will house 80% of the world's elderly. The elderly population is expected to grow, and this group is more vulnerable to eye-related disorders such as dry eye. This factor could influence the market in the future.

US Dry Eye Disease Market  is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 5.13 billion

Largest Segment

Anti-inflammatory Drugs

Fastest Growth

Anti-inflammatory Drugs

Growth Rate

7.85% CAGR

Country Share for North America Region (%)
Country Share for Aisa Pacific Region (%)

To get more reports on the above market click here to Buy The Report

Dry Eye Disease Market Segmental Analysis

The global dry eye disease market is segmented based on the product, distribution channel and region. Based on the product, it is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, and others. Based on distribution channel, the Dry Eye Disease Market is segmented into hospital pharmacies, independent pharmacies & drug stores, and online pharmacies. Based on region the Dry Eye Disease Market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Dry Eye Disease Market Analysis by Product

The global dry eye disease market is segmented based on product into females, and males. The anti-inflammatory segment accounted for the greatest share in 2021, owing to the fact that several key products belonged to this segment in 2021. However, artificial tears and lubricant eye drops were also important in the treatment of the disease. Rising product approvals and new product launches are also expected to drive the corticosteroid market. For Instance, in February 2021, the US Food and Drug Administration approved Akorn Operating Company LLC's Abbreviated New Drug Application (ANDA) for loteprednol etabonate ophthalmic gel 0.5%, which is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Global Dry Eye Disease Market By Product

To get detailed analysis on other segments, Request For Free Sample Report

Dry Eye Disease Market Regional Insights

The global dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

The region's ageing population is driving market growth because they are more susceptible to ophthalmic disorders such as DED. For instance, according to the Administration for Community Living (ACL) of the United States' May 2021 report, approximately 54.1 million people 65 and older lived in the country in 2019, accounting for approximately 16% of the total population, and this figure is expected to rise to 21.6% of the total population by 2040. As a result, these factors are expected to drive growth in the dry eye disease market in North America over the forecast period.

Global Dry Eye Disease Market By Region

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Dry Eye Disease Market Dynamics

Dry Eye Disease Market Driver

Increased Prevalence of Dry Eye Disease to Supplement Market Growth

  • Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the global dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

Dry Eye Disease Market Restraints

Limited Awareness Limit Market Growth

  • The general public is unaware of the importance of eye health. Many dry eye symptoms are misunderstood and can be easily treated or corrected with proper diagnosis and medications. People do not visit ophthalmologists on a regular basis unless they are experiencing severe symptoms. Dry eye symptoms such as redness, burning, and so on are frequently ignored and underdiagnosed, reducing the patient pool that can be treated with prescription drugs. According to a survey conducted in the United Kingdom, one out of every four adults does not have their eyes tested every two years as recommended by the NHS, with children having a higher level of ignorance about eye health.

Request Free Customization of this report to help us to meet your business objectives.

Dry Eye Disease Market Competitive Landscape

The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players.

Dry Eye Disease Market Top Company Profiles

  • Allergan plc (now part of AbbVie Inc.)
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Shire (now part of Takeda Pharmaceutical Company Limited)
  • Sun Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Alcon Inc. (a subsidiary of Novartis AG)
  • AbbVie Inc.
  • Akorn, Inc.
  • Nicox SA
  • Mitotech S.A.
  • Tarsus Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Novaliq GmbH
  • Oyster Point Pharma, Inc.
  • AFT Pharmaceuticals Ltd.
  • OcuSoft, Inc.
  • Eyenovia, Inc.

Dry Eye Disease Market Recent Developments

  • In July 2022, Aldeyra Therapeutics, Inc. announced that the primary endpoints of a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease had been met.
  • In January 2022, Avenova Lubricating Eye Drops were introduced by NovaBay Pharmaceuticals to treat dry eye symptoms.

Dry Eye Disease Key Market Trends

  • One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

Dry Eye Disease Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our global dry eye disease market analysis, Due to the high incidence of dry eye disorder and the potentially serious and chronic nature of the disease, the dry eye treatment market is experiencing significant growth. Dry eye disease is primarily treated with medications such as Xiidra and RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, which can cost up to $5,000 per year. These products are expensive; however, the large unmet need and high efficacy of the products drive their adoption. The increasing number of candidates in the pipelines of numerous major companies are expected to lead to certain regulatory approvals, further increasing the market size. Furthermore, drug launches are one of the key factors driving the region's market growth. For example, Kala Pharmaceuticals Inc. introduced EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% in January 2021 for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional pharmaceutical distribution centres throughout the United States. Patients with a prescription can get EYSUVIS at their local retail pharmacy or through home delivery.

Report Metric Details
Market size value in 2023 USD 5.13 billion
Market size value in 2031 USD 10.92 billion
Growth Rate 7.85%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Product
    • Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, Others
  • Distribution Channel
    • Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Allergan plc (now part of AbbVie Inc.)
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Shire (now part of Takeda Pharmaceutical Company Limited)
  • Sun Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Alcon Inc. (a subsidiary of Novartis AG)
  • AbbVie Inc.
  • Akorn, Inc.
  • Nicox SA
  • Mitotech S.A.
  • Tarsus Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Novaliq GmbH
  • Oyster Point Pharma, Inc.
  • AFT Pharmaceuticals Ltd.
  • OcuSoft, Inc.
  • Eyenovia, Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Dry Eye Disease Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Dry Eye Disease Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Dry Eye Disease Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Dry Eye Disease Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Dry Eye Disease Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Dry Eye Disease Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Dry Eye Disease Market size was valued at USD 5.13 billion in 2019 and is poised to grow from USD 5.53 billion in 2023 to USD 10.92 billion by 2031, growing at a CAGR of 7.85% in the forecast period (2024-2031).

The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players. 'Allergan plc (now part of AbbVie Inc.)', 'Novartis AG', 'Santen Pharmaceutical Co., Ltd.', 'Johnson & Johnson', 'Otsuka Pharmaceutical Co., Ltd.', 'Shire (now part of Takeda Pharmaceutical Company Limited)', 'Sun Pharmaceutical Industries Ltd.', 'Bausch Health Companies Inc.', 'Alcon Inc. (a subsidiary of Novartis AG)', 'AbbVie Inc.', 'Akorn, Inc.', 'Nicox SA', 'Mitotech S.A.', 'Tarsus Pharmaceuticals, Inc.', 'Kala Pharmaceuticals, Inc.', 'Novaliq GmbH', 'Oyster Point Pharma, Inc.', 'AFT Pharmaceuticals Ltd.', 'OcuSoft, Inc.', 'Eyenovia, Inc.'

Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

The dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Dry Eye Disease Market

Report ID: SQMIG35D2172

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE